NICE Launches a competition for developers of healthcare technologies
28 June 2017
NICE Scientific Advice has launched a competition for small or medium sized companies, charities and academic research groups, who are developing transformative products that have the potential to change patients’ lives and/or save the NHS money.
The NICE AdviSeME Prize is open to products (pharmaceuticals, devices, diagnostic test/tools, cell/gene therapies, healthcare apps) in the early clinical stages of development. To be considered the technologies should demonstrate clinical credibility and target a population with a high unmet clinical need. In addition they need to have a potential beneficial impact on either; survival and/or health-related quality of life, costs to the NHS or the use of healthcare resources and/or access to healthcare.
Organisations are invited to submit an application detailing their product development plans which will be assessed by the expert selection panel comprising Professor Sir Michael Rawlins (MHRA), Professor Carole Longson (NICE), Dr Ian Campbell (Innovate UK) and Professor Sue Hill (NHS England).
The winner will receive a free Light Scientific Advice Service from NICE, usually costing £15,000. The award will support discussions between the company and payers and commissioners to enable market access for their product. NICE will work with clinical and health economics experts to provide a comprehensive commentary on proposed evidence generation plans to help the organisation demonstrate the value of their product.
Leeza Osipenko, Head of NICE Scientific Advice, said: “The NICE AdviSeME Prize is a realisation of our commitment to supporting smaller organisations in the life sciences landscape and increasing the profile of their products by helping shape their development efforts to meet patient and healthcare system needs.”
NICE Scientific Advice provides a fee-based consultancy service to developers of pharmaceuticals, biopharmaceuticals, medical devices and diagnostics. It works with companies in the early stages of product development. Its aim is to help companies ensure that their clinical programmes collect data relevant for reimbursement decisions when assessing the clinical and cost effectiveness of new healthcare interventions.
The NICE AdviSeME prize will run from 27 June and the closing date for applications is 13 October 2017. Further information about the competition, including terms and conditions, is available on the NICE website.